Immunoassay cross-reactivity varies
The phase 3 SELECT trial highlighted semaglutide 2.4 mgs capability to cut the risk of major adverse cardiovascular events by 20% in individuals with obesity compared to a placebo, leading to an updated label for Wegovy
If the molecule is properly synthesized and formulated, it will bind the same receptors and trigger the same physiological responses
The modifications reduce binding to IGF binding proteins, extending its biological half-life relative to native IGF-1
If you have an underactive thyroid and are considering semaglutide for weight loss, understanding how these two conditions interact is essential for safe, effective treatment
If your goal is to come off the medication, the most successful approach is usually a planned, supported transition , rather than an abrupt stop with fingers crossed